Wall Street brokerages expect Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to announce earnings per share (EPS) of ($0.21) for the current quarter, Zacks reports. Three analysts have issued estimates for Lexicon Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.24) and the highest estimate coming in at ($0.18). Lexicon Pharmaceuticals reported earnings of ($0.40) per share during the same quarter last year, which indicates a positive year over year growth rate of 47.5%. The firm is scheduled to report its next earnings report on Thursday, May 2nd.

According to Zacks, analysts expect that Lexicon Pharmaceuticals will report full year earnings of ($0.59) per share for the current year, with EPS estimates ranging from ($0.95) to $0.23. For the next financial year, analysts forecast that the company will report earnings of ($0.72) per share, with EPS estimates ranging from ($1.60) to ($0.05). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.12. Lexicon Pharmaceuticals had a negative return on equity of 911.43% and a negative net margin of 192.53%. The firm had revenue of $17.10 million for the quarter, compared to analyst estimates of $13.33 million. During the same period last year, the company earned ($0.27) EPS. The firm’s quarterly revenue was down 49.7% on a year-over-year basis.

A number of analysts have issued reports on LXRX shares. Wedbush raised their price target on Lexicon Pharmaceuticals from $36.00 to $38.00 and gave the stock an “outperform” rating in a research note on Monday, March 4th. Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Monday, March 25th. ValuEngine downgraded Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, February 4th. Gabelli downgraded Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 13th. Finally, BidaskClub raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, January 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $17.13.

Several institutional investors and hedge funds have recently bought and sold shares of the company. CWM Advisors LLC raised its stake in shares of Lexicon Pharmaceuticals by 30.2% in the 4th quarter. CWM Advisors LLC now owns 13,059 shares of the biopharmaceutical company’s stock worth $87,000 after buying an additional 3,030 shares in the last quarter. Pegasus Asset Management Inc. bought a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter worth $66,000. Paloma Partners Management Co bought a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter worth $73,000. MetLife Investment Advisors LLC raised its stake in shares of Lexicon Pharmaceuticals by 49.8% in the 3rd quarter. MetLife Investment Advisors LLC now owns 35,705 shares of the biopharmaceutical company’s stock worth $381,000 after buying an additional 11,862 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY raised its stake in shares of Lexicon Pharmaceuticals by 409.3% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 14,760 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 11,862 shares in the last quarter. 99.16% of the stock is currently owned by institutional investors.

NASDAQ:LXRX traded down $0.08 during mid-day trading on Friday, reaching $5.58. The company’s stock had a trading volume of 645,697 shares, compared to its average volume of 906,341. Lexicon Pharmaceuticals has a twelve month low of $4.25 and a twelve month high of $13.97. The firm has a market cap of $611.06 million, a price-to-earnings ratio of -4.90 and a beta of 0.71.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Featured Article: Yield Curve

Get a free copy of the Zacks research report on Lexicon Pharmaceuticals (LXRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.